Peritoneal carcinomatosis from ovarian cancer: Chemosensitivity test and tissue markers as predictors of response to chemotherapy

Journal of Translational Medicine

Volumn 9, Issue 1, 2011, Pages

  Arienti, Chiara ^a   Tesei, Anna ^a   Verdecchia, Giorgio M ^b   Framarini, Massimo ^b   Virzì, Salvatore ^c   Grassi, Antonio ^c   Scarpi, Emanuela ^a   Turci, Livia ^a   Silvestrini, Rosella ^a   Amadori, Dino ^a   Zoli, Wainer ^a  

^a DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^b MORGAGNI PIERANTONI HOSPITAL   (Italy)

^c Ospedale di Bentivoglio   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOXORUBICIN; GEMCITABINE; PACLITAXEL; TUMOR MARKER;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOMATOUS PERITONITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESISTANCE; DRUG RESPONSE; DRUG SENSITIVITY; ERCC1 GENE; FEMALE; GENE; GENE EXPRESSION; GENETIC MARKER; GSTP1 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MGMT GENE; ONCOGENE; OVARY CANCER; PREDICTION; XPD GENE; DRUG EFFECT; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METASTASIS; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; PERITONEUM TUMOR; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CARBOPLATIN; CISPLATIN; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 79959196985     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-9-94     Document Type: Article

References (40)

1. Hamburger AW, Salmon SE. Primary bioassay of human tumor stem cells. Science 1977, 197:461-463. 10.1126/science.560061, 560061.
2. Kern DH, Drogemuller CR, Kennedy MC, Hildebrand-Zanki SU, Tanigawa N, Sondak VK. Development of a miniaturized, improved nucleic acid precursor incorporation assay for chemosensitivity testing of human solid tumors. Cancer Res 1985, 45:5436-5441.
3. Weisenthal LM, Marsden JA, Dill PL, Macaluso CK. A novel dye exclusion method for testing in vitro chemosensitivity of human tumors. Cancer Res 1983, 43:749-757.
4. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990, 82:1107-1112. 10.1093/jnci/82.13.1107, 2359136.
5. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 1987, 47:936-942.
6. Kangas L, Gronroos M, Nieminen AL. Bioluminescence of cellular ATP: a new method for evaluating cytotoxic agents in vitro. Med Biol 1984, 62:338-343.
7. Von Hoff DD, Clark GM, Stogdill BJ, Sarosdy MF, O'Brien MT, Casper JT, Mattox DE, Page CP, Cruz AB, Sandbach JF. Prospective clinical trial of a human tumor cloning system. Cancer Res 1983, 43:1926-1931.
8. Sondak VK, Bertelsen CA, Tanigawa N, Hildebrand-Zanki SU, Morton DL, Korn EL, Kern DH. Clinical correlations with chemosensitivities measured in a rapid thymidine incorporation assay. Cancer Res 1984, 44:1725-1728.
9. Bertelsen CA, Sondak VK, Mann BD, Korn EL, Kern DH. Chemosensitivity testing of human solid tumors. A review of 1582 assays with 258 clinical correlations. Cancer 1984, 53:1240-1245. 10.1002/1097-0142(19840315)53:6<1240::AID-CNCR2820530604>3.0.CO;2-Y, 6692313.
10. Keepers YP, Pizao PE, Peters GJ, van Ark-Otte J, Winograd B, Pinedo HM. Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing. Eur J Cancer 1991, 27:897-900. 10.1016/0277-5379(91)90142-Z, 1834124.
11. Richardson A, Kaye SB. Drug resistance in ovarian cancer: the emerging importance of gene transcription and spatio-temporal regulation of resistance. Drug Resist Updat 2005, 8:311-321. 10.1016/j.drup.2005.09.001, 16233989.
12. Bonnefoi H, A'Hern RP, Fisher C, Macfarlane V, Barton D, Blake P, Shepherd JH, Gore ME. Natural history of stage IV epithelial ovarian cancer. J Clin Oncol 1999, 17:767-775.
13. Funicelli L, Travaini LL, Landoni F, Trifiro' G, Bonello L, Bellomi M. Peritoneal carcinomatosis from ovarian cancer: the role of CT and [18F]FDG-PET/CTL.,4. Abdom Imaging 2010, 35:701-707. 10.1007/s00261-009-9578-8, 19784697.
14. Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, Wadler S, Sickel J. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001, 19:1001-1007.
15. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007, 7:573-584. 10.1038/nrc2167, 17625587.
16. Shirota Y, Stoehlmacher J, Brabender J, Xiong YP, Uetake H, Danenberg KD, Groshen S, Tsao-Wei DD, Danenberg PV, Lenz HJ. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001, 19:4298-4304.
17. Rosell R, Taron M, Barnadas A, Scagliotti G, Sarries C, Roig B. Nucleotide excision repair pathways involved in Cisplatin resistance in non-small-cell lung cancer. Cancer Control 2003, 10:297-305.
18. Weberpals J, Garbuio K, O'Brien A, Clark-Knowles K, Doucette S, Antoniouk O, Goss G, Dimitroulakos J. The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer. Int J Cancer 2009, 124:806-815. 10.1002/ijc.23987, 19035454.
19. Furuta T, Ueda T, Aune G, Sarasin A, Kraemer KH, Pommier Y. Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res 2002, 62:4899-4902.
20. Kaina B, Christmann M, Naumann S, Roos WP. MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair (Amst) 2007, 6:1079-1099.
21. Yarosh DB, Foote RS, Mitra S, Day RS. Repair of O6-methylguanine in DNA by demethylation is lacking in Mer- human tumor cell strains. Carcinogenesis 1983, 4:199-205. 10.1093/carcin/4.2.199, 6825208.
22. Quinn JE, Carser JE, James CR, Kennedy RD, Harkin DP. BRCA1 and implications for response to chemotherapy in ovarian cancer. Gynecol Oncol 2009, 113:134-142. 10.1016/j.ygyno.2008.12.015, 19168207.
23. Tassone P, Di Martino MT, Ventura M, Pietragalla A, Cucinotto I, Calimeri T, Bulotta A, Neri P, Caraglia M, Tagliaferri P. Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo. Cancer Biol Ther 2009, 8:648-653.
24. Lewis AD, Hayes JD, Wolf CR. Glutathione and glutathione-dependent enzymes in ovarian adenocarcinoma cell lines derived from a patient before and after the onset of drug resistance: intrinsic differences and cell cycle effects. Carcinogenesis 1988, 9:1283-1287. 10.1093/carcin/9.7.1283, 2898306.
25. Yang P, Ebbert JO, Sun Z, Weinshilboum RM. Role of the glutathione metabolic pathway in lung cancer treatment and prognosis: a review. J Clin Oncol 2006, 24:1761-1769. 10.1200/JCO.2005.02.7110, 16603718.
26. Siegel S. Nonparametric statistics. 1956, London: McGraw-Hill Ltd.
27. Eguchi S, Copas J. A class of logistic-type discriminant functions. Biometrika 2002, 89:1-22.
28. McIntosh MW, Pepe MS. Combining several screening tests: optimality of the risk score. Biometrics 2002, 58:657-664. 10.1111/j.0006-341X.2002.00657.x, 12230001.
29. Naniwa J, Kigawa J, Kanamori Y, Itamochi H, Oishi T, Shimada M, Shimogai R, Kawaguchi W, Sato S, Terakawa N. Genetic diagnosis for chemosensitivity with drug-resistance genes in epithelial ovarian cancer. Int J Gynecol Cancer 2007, 17:76-82. 10.1111/j.1525-1438.2006.00752.x, 17291235.
30. O'Toole SA, Sheppard BL, Laios A, O'Leary JJ, McGuinness EP, D'Arcy T, Bonnar J. Potential predictors of chemotherapy response in ovarian cancer--how do we define chemosensitivity?. Gynecol Oncol 2007, 104:345-351. 10.1016/j.ygyno.2006.08.039, 17027070.
31. Bignotti E, Tassi RA, Calza S, Ravaggi A, Romani C, Rossi E, Falchetti M, Odicino FE, Pecorelli S, Santin AD. Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy. Gynecol Oncol 2006, 103:405-416. 10.1016/j.ygyno.2006.03.056, 16725184.
32. Darcy KM, Birrer MJ. Translational research in the Gynecologic Oncology Group: evaluation of ovarian cancer markers, profiles, and novel therapies. Gynecol Oncol 2010, 117:429-439. 10.1016/j.ygyno.2010.01.048, 2877379, 20233625.
33. Santini D, Caraglia M, Vincenzi B, Holen I, Scarpa S, Budillon A, Tonini G. Mechanisms of disease: preclinical reports of antineoplastic synergistic action of bisphosphonates. Nat Clin Pract Oncol 2006, 3:325-338. 10.1038/ncponc0520, 16757970.
34. Codegoni AM, Broggini M, Pitelli MR, Pantarotto M, Torri V, Mangioni C, D'Incalci M. Expression of genes of potential importance in the response to chemotherapy and DNA repair in patients with ovarian cancer. Gynecol Oncol 1997, 65:130-137. 10.1006/gyno.1996.4609, 9103402.
35. Aloyz R, Xu ZY, Bello V, Bergeron J, Han FY, Yan Y, Malapetsa A, Alaoui-Jamali MA, Duncan AM, Panasci L. Regulation of cisplatin resistance and homologous recombinational repair by the TFIIH subunit XPD. Cancer Res 2002, 62:5457-5462.
36. Sevin BU, Peng ZL, Perras JP, Ganjei P, Penalver M, Averette HE. Application of an ATP-bioluminescence assay in human tumor chemosensitivity testing. Gynecol Oncol 1988, 31:191-204. 10.1016/0090-8258(88)90293-4, 3410347.
37. Smith HS, Zoli W, Volpi A, Hiller A, Lippman M, Swain S, Mayall B, Dollbaum C, Hackett AJ, Amadori D. Preliminary correlations of clinical outcome with in vitro chemosensitivity of second passage human breast cancer cells. Cancer Res 1990, 50:2943-2948.
38. Nagai N, Minamikawa K, Mukai K, Hirata E, Komatsu M, Kobayashi H. Predicting the chemosensitivity of ovarian and uterine cancers with the collagen gel droplet culture drug-sensitivity test. Anticancer Drugs 2005, 16:525-531. 10.1097/00001813-200506000-00008, 15846118.
39. Kim HA, Yom CK, Moon BI, Choe KJ, Sung SH, Han WS, Choi HY, Kim HK, Park HK, Choi SH, et al. The use of an in vitro adenosine triphosphate-based chemotherapy response assay to predict chemotherapeutic response in breast cancer. Breast 2008, 17:19-26. 10.1016/j.breast.2007.06.001, 17659874.
40. Cree IA, Kurbacher CM, Lamont A, Hindley AC, Love S. A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer. Anticancer Drugs 2007, 18:1093-1101. 10.1097/CAD.0b013e3281de727e, 17704660.